You are here

SBIR Phase II:Microbial Discovery and Biosynthesis of Targeted Protease Inhibitors (COVID-19)

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 2213051
Agency Tracking Number: 2213051
Amount: $1,000,000.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: PT
Solicitation Number: NSF 21-565
Solicitation Year: 2021
Award Year: 2023
Award Start Date (Proposal Award Date): 2022-12-01
Award End Date (Contract End Date): 2024-11-30
Small Business Information
2523 Broadway St, Ste 301
Boulder, CO 80304
United States
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Matthew Traylor
 (415) 728-1239
Business Contact
 Matthew Traylor
Phone: (415) 728-1239
Research Institution

The broader impact/commercial potential of this Small Business Innovation Research Phase II project is to develop a mature, market-ready approach for building targeted, readily synthesizable inhibitors of viral proteases. The technology will extend the discovery platform to new targets and disease indications and build a biochemical foundation for progressing preclinical programs to promising leads, starting with a potent lead candidate for treating COVID-19. The project seeks to generate new intellectual property that covers the discovery platform and promising small molecules, and it will support new opportunities to partner with pharmaceutical companies on antiviral therapeutics, which continue to be an important unmet medical need. _x000D_
This Small Business Innovation Research Phase II project seeks to expand and industrialize the company’s recently demonstrated approach for using microbial systems to guide the discovery and assembly of protease inhibitors. The project focuses on COVID-19 and other viral diseases that lack effective treatments, exhibit significant epidemic potential, and/or remain relevant to U.S. biodefense. The research program may uncover inhibitors of a broad set of viral proteases and as it screens large libraries of biosynthetic pathways for targeted inhibitors. This solution complements the multi-part effort by developing a potent lead candidate for treating COVID-19 and a general workflow for the (bio)synthetic optimization of hits identified. Success in these tasks may stretch contemporary approaches to synthetic biology by applying them to the discovery and assembly of new biologically active compounds and may develop a supporting (bio)synthetic workflow—one that that combines applied enzymology and synthetic chemistry._x000D_
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government